moxidectin and Respiratory-Tract-Infections

Troglostrongylus brevior is a lungworm of wild felids that recently has been recognized as agent of severe respiratory disease in domestic cats in Mediterranean and Balkan countries. Nevertheless, the information on treatment options for feline troglostrongylosis is still poor. The aim of this pilot field trial was to evaluate the efficacy of the spot-on formulation containing 1% w/v moxidectin and 10% w/v imidacloprid (Advocate. The trial was a negative control, multicentre, clinical efficacy study conducted according to the standards of Good Scientific Practice (GSP). Sixteen cats in two study sites, naturally infected with T. brevior, were allocated to an untreated control group (G1, n = 8) or a treatment group (G2, n = 8), according to a randomization list. Animals assigned to G2 were treated with Advocate. All G2 cats were negative for T. brevior L1 at the first post-treatment evaluation (100% efficacy) while G1 cats were persistently shedding L1. The difference of the mean number of L1 per gram between G2 and G1 was statistically significant (P < 0.001). All G1 cats were negative (100% efficacy) for T. brevior L1 at the first post-rescue-treatment evaluation. Therefore, treatment efficacy at study completion was 100% in both groups in terms of stopping the L1 shedding in the faeces of the animals. No adverse effects were observed during the study.. These results indicate that Advocate

Topics: Animals; Cat Diseases; Cats; Drug Combinations; Feces; Female; Greece; Larva; Macrolides; Male; Metastrongyloidea; Neonicotinoids; Nitro Compounds; Respiratory Tract Infections; Strongylida Infections

Topics: Administration, Topical; Animals; Antinematodal Agents; Capillaria; Dog Diseases; Dogs; Drug Combinations; Enoplida Infections; Female; Imidazoles; Macrolides; Neonicotinoids; Nitro Compounds; Respiratory Tract Infections; Treatment Outcome